Journal article
Oral Human Papillomavirus in Men Having Sex with Men: Risk-Factors and Sampling
TRH Read, JS Hocking, LA Vodstrcil, SN Tabrizi, MJ McCullough, AE Grulich, SM Garland, CS Bradshaw, MY Chen, CK Fairley
Plos One | Published : 2012
Open access
Abstract
Background: Human papillomavirus (HPV)-associated oropharyngeal squamous cell carcinoma is becoming more common. We examined prevalence and risk factors for oral HPV among men who have sex with men (MSM) and compared sampling and transport methods. Methods: In 2010, 500 MSM (249 HIV-positive) attending Melbourne Sexual Health Centre answered a questionnaire, swabbed their mouth and throat and collected a gargled oral rinse sample. Half the oral rinse was transported absorbed in a tampon (to enable postage). HPV was detected by polymerase chain reaction, and genotyped by Roche Linear Array®. Men with HPV 16 or 18 were retested after six months. Results: Any HPV genotype was detected in 19% (9..
View full abstractRelated Projects (2)
Grants
Awarded by National Health and Medical Research Council of Australia
Funding Acknowledgements
[ "This study was funded by Program Grant number 568971 of the National Health and Medical Research Council of Australia. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.", "CKF, JSH and AEG have received honoraria from CSL Biotherapies. CKF and AEG have received research funding from CSL Biotherapies. CKF owns shares in CSL Biotherapies, the manufacturer of Gardasil, and has received honoraria from Merck. SMG has received advisory board fees and grant support from Commonwealth Serum Laboratories and GlaxoSmithKline, and lecture fees from Merck and Sanofi Pasteur MSD. In addition, she has received funding through her institutions to conduct HPV vaccine studies for GlaxoSmithKline and for Merck. AEG has received honoraria and travel funding from Merck, and sits on the Australian advisory board for the Gardasil vaccine. TRHR is a site investigator on a Merck-sponsored study. MYC, SNT, MJM and CSB, have no conflicts of interest. This does not alter the authors' adherence to all the PLOS ONE policies on sharing data and materials." ]